Literature DB >> 21286347

Fluidized-bed bioartificial liver assist devices (BLADs) based on microencapsulated primary porcine hepatocytes have risk of porcine endogenous retroviruses transmission.

Qian Yang1, Fei Liu, Xiao Ping Pan, Guoliang Lv, Anye Zhang, Chen Bo Yu, Lanjuan Li.   

Abstract

PURPOSE: Bioartificial liver assist devices (BLADs) are expected to bridge liver failure patients to liver transplantation, but porcine endogenous retroviruses (PERVs) still pose a potential risk in pig-to-human xenotransplantation and thereby limit the use of bioartificial liver therapy. In our lab, fluidized-bed BLADs based on microencapsulated primary porcine hepatocytes have been successfully used to treat liver failure pigs. We detected the risk of PERVs transmission of microencapsulated primary porcine hepatocytes-the key component of fluidized-bed BLADs, to evaluate the biosafety of this device for further clinical applications.
METHODS: Microencapsulated primary porcine hepatocytes (cell diameter = 300 μm) were cultured in Dulbecco's modified Eagles medium (DMEM). Microencapsulated cell culture supernatants were collected at 6, 12, 24 and 72 h. HEK-293 were cocultured with these supernatants, and the cocultured cells were harvested every 7 days. RT-PCR was used to detect PERVs transmission. RT-qPCR was used to get the number of virus copies. PK-15 was used as the positive control whereas HepG2 was used as the negative control.
RESULTS: PERV was detected in all supernatants, and the viral load of the supernatants increased with time. Moreover, cocultured 293 cells were positive for PERV-specific sequences.
CONCLUSION: The kind of fluidized-bed BLADs based on microencapsulated primary porcine hepatocytes have risk of PERVs transmission. Further extensive pre-clinical study focused on biosafety is warranted.

Entities:  

Keywords:  Bioartificial liver assist devices; Microencapsulated primary porcine hepatocytes; Porcine endogenous retroviruses; RT-PCR; RT-qPCR

Year:  2010        PMID: 21286347      PMCID: PMC2994615          DOI: 10.1007/s12072-010-9210-6

Source DB:  PubMed          Journal:  Hepatol Int        ISSN: 1936-0533            Impact factor:   6.047


  23 in total

Review 1.  Artificial and bioartificial liver support: a review of perfusion treatment for hepatic failure patients.

Authors:  Katsutoshi Naruse; Wei Tang; Masatoshi Makuuch
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 2.  Encapsulated cell technology.

Authors:  R P Lanza; J L Hayes; W L Chick
Journal:  Nat Biotechnol       Date:  1996-09       Impact factor: 54.908

3.  Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure.

Authors:  A J Ellis; R D Hughes; J A Wendon; J Dunne; P G Langley; J H Kelly; G T Gislason; N L Sussman; R Williams
Journal:  Hepatology       Date:  1996-12       Impact factor: 17.425

4.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.

Authors:  F D Watanabe; C J Mullon; W R Hewitt; N Arkadopoulos; E Kahaku; S Eguchi; T Khalili; W Arnaout; C R Shackleton; J Rozga; B Solomon; A A Demetriou
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

5.  Porcine endogenous retrovirus infects but does not replicate in nonhuman primate primary cells and cell lines.

Authors:  Armin Ritzhaupt; Luc J W Van Der Laan; Daniel R Salomon; Carolyn A Wilson
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Infection of human cells by an endogenous retrovirus of pigs.

Authors:  C Patience; Y Takeuchi; R A Weiss
Journal:  Nat Med       Date:  1997-03       Impact factor: 53.440

7.  Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients.

Authors:  G V Mazariegos; D J Kramer; R C Lopez; A O Shakil; A J Rosenbloom; M DeVera; M Giraldo; T A Grogan; Y Zhu; M L Fulmer; B P Amiot; J F Patzer
Journal:  ASAIO J       Date:  2001 Sep-Oct       Impact factor: 2.872

Review 8.  Artificial and bioartificial liver support.

Authors:  Travis J McKenzie; Joseph B Lillegard; Scott L Nyberg
Journal:  Semin Liver Dis       Date:  2008-05       Impact factor: 6.115

9.  Porcine endogenous retrovirus released by a bioartificial liver infects primary human cells.

Authors:  Jan-Henning Frühauf; Heike Mertsching; Shibashish Giri; Nils Roman Frühauf; Augustinus Bader
Journal:  Liver Int       Date:  2009-08-14       Impact factor: 5.828

10.  The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--chapter 5: Strategies to prevent transmission of porcine endogenous retroviruses.

Authors:  Joachim Denner; Henk-Jan Schuurman; Clive Patience
Journal:  Xenotransplantation       Date:  2009 Jul-Aug       Impact factor: 3.907

View more
  1 in total

Review 1.  Cell sources, liver support systems and liver tissue engineering: alternatives to liver transplantation.

Authors:  Soo Young Lee; Han Joon Kim; Dongho Choi
Journal:  Int J Stem Cells       Date:  2015-05       Impact factor: 2.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.